Insider Transactions in Q1 2021 at Biogen Inc. (BIIB)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 12
2021
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,896
-2.32%
|
$1,083,088
$278.03 P/Share
|
|
Feb 12
2021
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,355
+3.34%
|
-
|
|
Feb 12
2021
|
Alphonse Galdes EVP Pharmaceutical Oper & Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
715
-4.33%
|
$198,770
$278.03 P/Share
|
|
Feb 12
2021
|
Alphonse Galdes EVP Pharmaceutical Oper & Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
1,573
+10.76%
|
-
|
|
Feb 12
2021
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
2,182
-6.72%
|
$606,596
$278.03 P/Share
|
|
Feb 12
2021
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
2,923
+10.58%
|
-
|
|
Feb 12
2021
|
Chirfi Guindo Head of Glob Prod Strat & Com |
SELL
Payment of exercise price or tax liability
|
Direct |
940
-7.01%
|
$261,320
$278.03 P/Share
|
|
Feb 12
2021
|
Chirfi Guindo Head of Glob Prod Strat & Com |
BUY
Exercise of conversion of derivative security
|
Direct |
3,156
+20.65%
|
-
|
|
Feb 12
2021
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
115
-8.47%
|
$31,970
$278.03 P/Share
|
|
Feb 12
2021
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
333
+21.38%
|
-
|
|
Feb 12
2021
|
Alfred Sandrock Head of Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
3,510
-4.88%
|
$975,780
$278.03 P/Share
|
|
Feb 12
2021
|
Alfred Sandrock Head of Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
4,454
+7.56%
|
-
|
|
Feb 12
2021
|
Michel Vounatsos Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,473
-6.67%
|
$4,023,494
$278.03 P/Share
|
|
Feb 12
2021
|
Michel Vounatsos Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,289
+9.06%
|
-
|
|
Feb 09
2021
|
Jesus B Mantas Director |
BUY
Open market or private purchase
|
Direct |
898
+23.38%
|
$239,766
$267.0 P/Share
|
|
Jan 27
2021
|
Michel Vounatsos Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,343
+24.21%
|
-
|
|
Jan 27
2021
|
Alfred Sandrock Head of Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
3,728
+18.17%
|
-
|
|
Jan 27
2021
|
Ginger Gregory EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
2,558
+26.08%
|
-
|
|
Jan 27
2021
|
Alphonse Galdes EVP Pharmaceutical Oper & Tech |
BUY
Grant, award, or other acquisition
|
Direct |
818
+19.19%
|
-
|
|
Jan 27
2021
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,545
+9.95%
|
-
|